Lv3
238 积分 2021-03-11 加入
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease
14天前
已完结
中国多发性骨髓瘤诊治指南（2026年修订）
16天前
已完结
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
23天前
已完结
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2个月前
已完结
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
2个月前
已完结
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia
2个月前
已完结
CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma
3个月前
已完结
血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则
3个月前
已完结
Delay differential equation (DDE) modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies
3个月前
已完结
皖公网安备34019202002308
